(MENAFN- GlobeNewsWire - Nasdaq) AI, real-world evidence and precision medicine are accelerating drug repurposing, creating opportunities in rare diseases, failed-drug re-evaluation and pharma-CRO partnerships.Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE) -- "Drug Repositioning Service Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Drug Repositioning Service Market to Reach $45.92 Billion by 2030 as AI Adoption Accelerates
The global drug repositioning service market is experiencing strong growth as pharmaceutical and biotechnology organizations seek faster, more cost-effective approaches to drug development. The market is projected to increase from $34.2 billion in 2025 to $36.19 billion in 2026, representing a compound annual growth rate (CAGR) of 5.8%.
Historical market growth has been supported by rising pharmaceutical research and development costs, the availability of extensive legacy drug data, an increasing number of failed clinical trials and demand for shorter drug development cycles. Early adoption of computational drug discovery technologies has also enabled researchers to identify new therapeutic applications for existing compounds more efficiently.
Looking ahead, the drug repositioning service market is forecast to reach $45.92 billion by 2030, expanding at a CAGR of 6.1%. Growth during the forecast period is expected to be driven by increasing demand for cost-efficient drug development, broader adoption of artificial intelligence-powered discovery tools and greater emphasis on rare and orphan diseases. The expansion of data-driven clinical research and increasing regulatory acceptance of repurposed drugs are also expected to support market development.
Key drug repositioning market trends include the growing use of AI-based drug repurposing platforms, renewed evaluation of drug candidates that previously failed in clinical trials and greater integration of real-world evidence into drug discovery programs. Precision medicine-focused repositioning strategies are gaining momentum, while collaboration among pharmaceutical companies, biotechnology businesses and contract research organizations is strengthening the industry's research capabilities.
Increasing healthcare expenditure is expected to remain an important driver of market growth. Higher medical costs, continued technological advancement and rising demand for healthcare services are leading to greater investment in research and clinical development. Additional funding can support more clinical trials and accelerate the identification of new therapeutic applications for existing drugs. According to the UK Office for National Statistics, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023.
Artificial intelligence is becoming increasingly important across the drug repositioning service market. Companies are using computational platforms to analyze scientific literature, biological information, existing compounds and clinical data. These technologies can improve the transition from hypothesis generation to experimental validation while helping researchers uncover previously unreported relationships between diseases and potential treatments.
In November 2024, Japan-based UBE and FRONTEO initiated a co-creation project designed to advance drug repositioning research. The initiative combines data analysis with biological testing to improve collaboration across the discovery and validation process. It also applies FRONTEO's Drug Discovery AI Factory and KIBIT technology to identify new relationships between diseases and molecules.
Strategic acquisitions are further shaping the competitive landscape. In January 2024, US-based healthcare group Cosmos Health Inc. acquired the Cloudscreen platform from Greece-based Cloudpharm P.C. for an undisclosed amount. The acquisition is intended to support Cosmos Health's drug repurposing initiatives by using Cloudscreen's AI capabilities to identify potential new therapeutic applications for existing medicines more effectively.
Drug repositioning services enable pharmaceutical companies to identify additional uses for existing drugs, strengthen the value of established portfolios and reduce some of the risks associated with developing entirely new compounds. By applying existing clinical evidence, biological research and advanced analytics, service providers can help shorten development timelines and lower costs while supporting the delivery of effective treatments.
The market includes services for generic medicines and drugs that failed during clinical trials. Key therapeutic areas include oncology, neurology, infectious diseases and cardiovascular diseases, alongside other clinical applications. Drug repositioning services are used by pharmaceutical companies, biotechnology firms, contract research organizations, academic research institutions, hospitals and ambulatory surgical centers.
North America was the largest regional market for drug repositioning services in 2025, while Asia-Pacific is expected to record the fastest growth during the forecast period. The market spans Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy and Spain.
Markets Covered:
1) By Type: Generic Drugs; Clinical Trial Failed Drugs
2) By Therapeutic Area: Oncology; Neurology; Infectious Diseases; Cardiovascular Diseases; Other Therapeutic Area
3) By End-User: Pharmaceutical Companies; Biotechnology Firms; Contract Research Organizations (CROs); Academic Research Institutions; Hospitals And Ambulatory Surgical Centers.
Subsegments:
1) By Generic Drugs: Small Molecule Drugs; Biologics; Biosimilars; Peptide-Based Drugs
2) By Clinical Trial Failed Drugs: Phase I Failed Drugs; Phase II Failed Drugs; Phase III Failed Drugs; Safety-Related Failed Drugs; Efficacy-Related Failed Drugs
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment